Logo image of GNFT

GENFIT-ADR (GNFT) Stock Fundamental Analysis

USA - NASDAQ:GNFT - US3722791098 - ADR

4.33 USD
-0.05 (-1.14%)
Last: 9/19/2025, 11:18:12 AM
Fundamental Rating

4

GNFT gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 540 industry peers in the Biotechnology industry. While GNFT is still in line with the averages on profitability rating, there are concerns on its financial health. GNFT is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

In the past year GNFT was profitable.
GNFT had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: GNFT reported negative net income in multiple years.
The reported operating cash flow has been mixed in the past 5 years: GNFT reported negative operating cash flow in multiple years.
GNFT Yearly Net Income VS EBIT VS OCF VS FCFGNFT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M -100M

1.2 Ratios

With an excellent Return On Assets value of 1.00%, GNFT belongs to the best of the industry, outperforming 89.63% of the companies in the same industry.
GNFT has a better Return On Equity (2.18%) than 91.11% of its industry peers.
GNFT's Return On Invested Capital of 3.45% is amongst the best of the industry. GNFT outperforms 91.30% of its industry peers.
Industry RankSector Rank
ROA 1%
ROE 2.18%
ROIC 3.45%
ROA(3y)-8.87%
ROA(5y)-10.74%
ROE(3y)-21.81%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
GNFT Yearly ROA, ROE, ROICGNFT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 600

1.3 Margins

Looking at the Profit Margin, with a value of 2.12%, GNFT belongs to the top of the industry, outperforming 90.19% of the companies in the same industry.
In the last couple of years the Profit Margin of GNFT has declined.
GNFT has a better Operating Margin (4.55%) than 90.56% of its industry peers.
In the last couple of years the Operating Margin of GNFT has declined.
GNFT's Gross Margin of 97.11% is amongst the best of the industry. GNFT outperforms 96.67% of its industry peers.
In the last couple of years the Gross Margin of GNFT has remained more or less at the same level.
Industry RankSector Rank
OM 4.55%
PM (TTM) 2.12%
GM 97.11%
OM growth 3Y-50.59%
OM growth 5YN/A
PM growth 3Y-69.99%
PM growth 5YN/A
GM growth 3Y-0.4%
GM growth 5Y0.52%
GNFT Yearly Profit, Operating, Gross MarginsGNFT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K

More info and screens

3

2. Health

2.1 Basic Checks

GNFT has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
GNFT has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, GNFT has more shares outstanding
GNFT has a worse debt/assets ratio than last year.
GNFT Yearly Shares OutstandingGNFT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
GNFT Yearly Total Debt VS Total AssetsGNFT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

GNFT has an Altman-Z score of -1.58. This is a bad value and indicates that GNFT is not financially healthy and even has some risk of bankruptcy.
GNFT has a Altman-Z score (-1.58) which is in line with its industry peers.
GNFT has a debt to FCF ratio of 4.26. This is a neutral value as GNFT would need 4.26 years to pay back of all of its debts.
GNFT has a better Debt to FCF ratio (4.26) than 92.96% of its industry peers.
GNFT has a Debt/Equity ratio of 0.08. This is a healthy value indicating a solid balance between debt and equity.
GNFT has a worse Debt to Equity ratio (0.08) than 63.15% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF 4.26
Altman-Z -1.58
ROIC/WACC0.49
WACC7%
GNFT Yearly LT Debt VS Equity VS FCFGNFT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

A Current Ratio of 1.23 indicates that GNFT should not have too much problems paying its short term obligations.
The Current ratio of GNFT (1.23) is worse than 84.81% of its industry peers.
GNFT has a Quick Ratio of 1.23. This is a normal value and indicates that GNFT is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.23, GNFT is doing worse than 84.26% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.23
Quick Ratio 1.23
GNFT Yearly Current Assets VS Current LiabilitesGNFT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 105.17% over the past year.
Measured over the past years, GNFT shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -70.77% on average per year.
Looking at the last year, GNFT shows a very strong growth in Revenue. The Revenue has grown by 85.82%.
Measured over the past years, GNFT shows a quite strong growth in Revenue. The Revenue has been growing by 11.61% on average per year.
EPS 1Y (TTM)105.17%
EPS 3Y-70.77%
EPS 5YN/A
EPS Q2Q%-212.5%
Revenue 1Y (TTM)85.82%
Revenue growth 3Y-6.06%
Revenue growth 5Y11.61%
Sales Q2Q%-53%

3.2 Future

Based on estimates for the next years, GNFT will show a very negative growth in Earnings Per Share. The EPS will decrease by -29.14% on average per year.
The Revenue is expected to decrease by -0.27% on average over the next years.
EPS Next Y53.49%
EPS Next 2Y-94%
EPS Next 3Y-42.79%
EPS Next 5Y-29.14%
Revenue Next Year-6.23%
Revenue Next 2Y-22.29%
Revenue Next 3Y-5.19%
Revenue Next 5Y-0.27%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
GNFT Yearly Revenue VS EstimatesGNFT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M
GNFT Yearly EPS VS EstimatesGNFT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 0.5 -0.5 -1 -1.5 -2

More info and screens

6

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 108.25 indicates a quite expensive valuation of GNFT.
Based on the Price/Earnings ratio, GNFT is valued cheaply inside the industry as 90.00% of the companies are valued more expensively.
GNFT is valuated expensively when we compare the Price/Earnings ratio to 27.41, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 6.51, which indicates a rather cheap valuation of GNFT.
GNFT's Price/Forward Earnings ratio is rather cheap when compared to the industry. GNFT is cheaper than 97.96% of the companies in the same industry.
GNFT's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 22.88.
Industry RankSector Rank
PE 108.25
Fwd PE 6.51
GNFT Price Earnings VS Forward Price EarningsGNFT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80 100

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, GNFT is valued cheaply inside the industry as 91.67% of the companies are valued more expensively.
GNFT's Price/Free Cash Flow ratio is rather cheap when compared to the industry. GNFT is cheaper than 97.22% of the companies in the same industry.
Industry RankSector Rank
P/FCF 12.57
EV/EBITDA 33.49
GNFT Per share dataGNFT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.5 1 1.5

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates GNFT does not grow enough to justify the current Price/Earnings ratio.
GNFT has a very decent profitability rating, which may justify a higher PE ratio.
GNFT's earnings are expected to decrease with -42.79% in the coming years. This may justify a cheaper valuation.
PEG (NY)2.02
PEG (5Y)N/A
EPS Next 2Y-94%
EPS Next 3Y-42.79%

More info and screens

0

5. Dividend

5.1 Amount

GNFT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GENFIT-ADR

NASDAQ:GNFT (9/19/2025, 11:18:12 AM)

4.33

-0.05 (-1.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-22 2025-05-22
Earnings (Next)09-22 2025-09-22
Inst Owners1%
Inst Owner Change-73.55%
Ins Owners0.18%
Ins Owner ChangeN/A
Market Cap216.51M
Analysts90.77
Price Target10.8 (149.42%)
Short Float %0.07%
Short Ratio9.97
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.94%
PT rev (3m)-0.28%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)924.96%
EPS NY rev (3m)925.94%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0.27%
Revenue NY rev (3m)-9.09%
Valuation
Industry RankSector Rank
PE 108.25
Fwd PE 6.51
P/S 2.58
P/FCF 12.57
P/OCF 11.78
P/B 2.65
P/tB 8.63
EV/EBITDA 33.49
EPS(TTM)0.04
EY0.92%
EPS(NY)0.67
Fwd EY15.37%
FCF(TTM)0.34
FCFY7.95%
OCF(TTM)0.37
OCFY8.49%
SpS1.68
BVpS1.64
TBVpS0.5
PEG (NY)2.02
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 1%
ROE 2.18%
ROCE 4.23%
ROIC 3.45%
ROICexc N/A
ROICexgc N/A
OM 4.55%
PM (TTM) 2.12%
GM 97.11%
FCFM 20.54%
ROA(3y)-8.87%
ROA(5y)-10.74%
ROE(3y)-21.81%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-50.59%
OM growth 5YN/A
PM growth 3Y-69.99%
PM growth 5YN/A
GM growth 3Y-0.4%
GM growth 5Y0.52%
F-Score7
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF 4.26
Debt/EBITDA 1.12
Cap/Depr 56.79%
Cap/Sales 1.38%
Interest Coverage 250
Cash Conversion 314.19%
Profit Quality 966.82%
Current Ratio 1.23
Quick Ratio 1.23
Altman-Z -1.58
F-Score7
WACC7%
ROIC/WACC0.49
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)105.17%
EPS 3Y-70.77%
EPS 5YN/A
EPS Q2Q%-212.5%
EPS Next Y53.49%
EPS Next 2Y-94%
EPS Next 3Y-42.79%
EPS Next 5Y-29.14%
Revenue 1Y (TTM)85.82%
Revenue growth 3Y-6.06%
Revenue growth 5Y11.61%
Sales Q2Q%-53%
Revenue Next Year-6.23%
Revenue Next 2Y-22.29%
Revenue Next 3Y-5.19%
Revenue Next 5Y-0.27%
EBIT growth 1Y112.1%
EBIT growth 3Y-53.58%
EBIT growth 5YN/A
EBIT Next Year67.69%
EBIT Next 3Y62.39%
EBIT Next 5YN/A
FCF growth 1Y125.16%
FCF growth 3Y-47.27%
FCF growth 5YN/A
OCF growth 1Y128.05%
OCF growth 3Y-46.21%
OCF growth 5YN/A